scholarly journals Donor cell‐derived chronic myelomonocytic leukemia presenting after allogeneic hematopoietic cell transplantation for T‐cell acute lymphoblastic leukemia

2020 ◽  
Vol 8 (12) ◽  
pp. 3225-3228
Author(s):  
Kevin C. Miller ◽  
Zaid H. Abdel Rahman ◽  
Ryan S. Robetorye ◽  
James M. Foran
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Lymphoblastic Leukemia ◽  
Donor Cell ◽  
Chronic Myelomonocytic Leukemia ◽  
Hematopoietic Cell ◽  
Cell Acute Lymphoblastic Leukemia ◽  
Myelomonocytic Leukemia

scholarly journals Relapsed Babesia microti Infection following Allogeneic Hematopoietic Cell Transplantation in a Patient with B-Cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature

2021 ◽  
Author(s):  
Joshua Rosenblatt ◽  
Annie Leung ◽  
Emily Baneman ◽  
Risa Fuller ◽  
Sarah Taimur ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
B Cell ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Lymphoblastic Leukemia ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Babesia Microti ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Cell Acute Lymphoblastic Leukemia

Abstract A patient with relapsed/refractory B-cell acute lymphoblastic leukemia developed babesiosis prior to allogeneic hematopoietic cell transplantation while on atovaquone for Pneumocystis jirovecii pneumonia prophylaxis. Despite receiving a prolonged course of atovaquone and azithromycin until whole blood Babesia microti DNA was no longer detected by polymerase chain reaction, her post-transplant course was complicated by relapsed babesiosis. We investigate the potential host and parasite characteristics causing relapsing/persistent infection.

Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia

Blood ◽  
2021 ◽  
Author(s):  
Mahmoud R. Gaballa ◽  
Pinaki Prosad Banerjee ◽  
Denái R. Milton ◽  
Xianli Jiang ◽  
Christina Ganesh ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
T Cell ◽  
High Risk ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Lymphoblastic Leukemia ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
T Cell Subsets ◽  
B Lineage

Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single center phase II study evaluating the feasibility of 4 cycles of blinatumomab administered every 3 months during the first year after HCT in an effort to mitigate relapse in high-risk ALL patients. Twenty-one of 23 enrolled patients received at least one cycle of blinatumomab and were included in the analysis. The median time from HCT to the first cycle of blinatumomab was 78 days (range, 44-105). Twelve patients (57%) completed all 4 treatment cycles. Neutropenia was the only grade 4 adverse event (19%). Rates of cytokine release (5% G1) and neurotoxicity (5% G2) were minimal. The cumulative incidence of acute GVHD grades 2-4 and 3-4 were 33% and 5%, respectively; two cases of mild (10%) and one case of moderate (5%) chronic GVHD were noted. With a median follow-up of 14.3 months, the 1-year overall survival, progression-free survival, and non-relapse mortality rates were 85%, 71%, and 0%, respectively. In a matched-analysis with a contemporary cohort of 57 patients, we found no significant difference between groups regarding blinatumomab's efficacy. Correlative studies of baseline and post-treatment samples identified patients with specific T-cell profiles as "responders" or "non-responders" to therapy. Responders had higher proportions of effector memory CD8 T-cell subsets. Non-responders were T-cell deficient and expressed more inhibitory checkpoint molecules, including TIM3. We found that blinatumomab post-allogeneic HCT is feasible, and its benefit is dependent on the immune milieu at time of treatment.

Sign in / Sign up

Export Citation Format

Share Document